Active, Not Recruiting
Real-Life Efficacy and Safety of Nivolumab in Patients With Advanced Renal Cell Carcinoma After Prior Therapy - CA209-653
Actualizada:
18 mayo, 2022
|
ClinicalTrials.gov
Géneros
Rango de edad
Active, Not Recruiting
Inclusion Criteria: - ≥ 18 years - diagnosis of advanced RCC (confirmed by histology or cytology) - treatment decision to initiate a treatment with nivolumab for the first time for the treatment of RCC (according to the label approved in Germany) has already been taken - signed informed consent Exclusion Criteria: - diagnosis of a cancer other than advanced RCC within the past 5 years, ie, a cancer other than RCC that requires systemic or other treatment. Patients that have been treated curatively more than 5 years ago with no evidence of recurrence and prostate cancer patients in active surveillance can be included - previous treatment with nivolumab and/or ipilimumab - current active participation in an interventional clinical trial for treatment of their advanced RCC.
Recomendamos encarecidamente que se comunique con BMS para informar los efectos secundarios (eventos adversos)
Los efectos secundarios (eventos adversos) y otros eventos reportables se definen aquí
Informe de efectos secundarios (eventos adversos) o quejas sobre la calidad del producto: información médica